Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Appian Corp (APPN) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Appian CorpTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Appian Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.57 (market cap $29.60B), while Appian Corp trades at $34.35 (market cap $2.54B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.7× Appian Corp's market cap, and Appian Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYAPPN
Market Cap
$29.60B$2.54B
Sector
HealthTechnology
52-Week High
$491.22$45.64
52-Week Low
$205.48$18.72
Enterprise Value
$27.56B$2.67B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.

The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.

Appian Corp

Appian Corporation (APPN) trades at $35.05, down 1.49% on the day, following a series of recent earnings beats. The stock exhibits a bullish technical trend with strong moving average support, though oscillators signal overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $727 million in 2025, and has achieved positive net income after years of losses, yet maintains a negative shareholder equity position. Recent news highlights strategic AI partnerships and strong quarterly performance.

The outlook is cautiously optimistic, driven by AI-driven demand and enterprise growth, but significant risks persist, including high valuation multiples, negative equity, and intense competition. Analyst consensus is mixed, with a majority Hold rating, suggesting the stock may be fully valued near-term despite operational improvements.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Appian Corp

Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.

Read more on APPN